Nabriva Therapeutics plc (NBRV) reported Q3 EPS of ($4.21), $0.18 worse than the analyst estimate of ($4.03). Revenue for the quarter came in at $9.15 million versus the consensus...
Investing.com - Nabriva (NASDAQ:NBRV) Therapeutics reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that fell short of...
Investing.com - Nabriva (NASDAQ:NBRV) Therapeutics reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that topped expectations. Nabriva...
Investing.com - Nabriva (NASDAQ:NBRV) Therapeutics reported on Thursday first quarter earnings that missed analysts' forecasts and revenue that fell short of...
Investing.com - Nabriva (NASDAQ:NBRV) Therapeutics reported on Tuesday first quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. Nabriva...
Investing.com - Nabriva (NASDAQ:NBRV) Therapeutics reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations. Nabriva...
Investing.com - Nabriva (NASDAQ:NBRV) Therapeutics reported on Thursday second quarter earnings that missed analysts' forecasts and revenue that fell short of...
Arbutus Biopharma (NASDAQ:ABUS) Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to...